Neuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04 ...

Ozempic, Zepbound, Wegovy, and other GLP-1 medications have transformed the way we lose weight. People who take them report life-changi ...

Despite constraints exerted by GLP-1RAs on bariatric surgery volumes, shares in Intuitive Surgical surged following a ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

PMGC Research Inc., formerly Elevai Research Inc., is a development company focused on public-private collaborations leveraging research ...

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...